Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Agammaglobulinaemia Tyrosine Kinase
/ antagonists & inhibitors
Animals
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Humans
Immunologic Factors
/ therapeutic use
Lymphoma, Mantle-Cell
/ drug therapy
Neoplasm Recurrence, Local
/ drug therapy
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins c-bcl-2
/ antagonists & inhibitors
Journal
Clinical advances in hematology & oncology : H&O
ISSN: 1543-0790
Titre abrégé: Clin Adv Hematol Oncol
Pays: United States
ID NLM: 101167661
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
17
6
2021
Statut:
ppublish
Résumé
Although chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.
Substances chimiques
Antineoplastic Agents
0
Immunologic Factors
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins c-bcl-2
0
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM